Tejal Patel

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer

Sergio Granados‐Principal, Yi Liu, María L. Guevara et al. · Breast Cancer Research · 2015 · 224 citations · Full text

Medicine, Oncology, Pharmacology +15

A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer

Andrew W. Chung, Kartik Anand, Ann C. Anselme et al. · Science Translational Medicine · 2021 · 109 citations

Medicine, Oncology, Pharmacology +10

Correlating mammographic and pathologic findings in clinical decision support using natural language processing and data mining methods

Tejal Patel, Mamta Puppala, Richard Ogunti et al. · Cancer · 2016 · 78 citations · Full text

Computing, Biomedical Informatics, Pathology +17

Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients

Diana H. Liang, Zhe-Bin Liu, Asmita Patel et al. · Breast Cancer Research and Treatment · 2015 · 59 citations

Medicine, Molecular Biology, Oncology +14